Catalog No.
DHE03402
Expression system
Mammalian Cells
Species reactivity
Human
Isotype
Fusion - [CTLA4 (cytotoxic T-lymphocyte-associated protein 4, CD152)]2 - IGHG1 Fc (Fragment constant)
Target
CD80, BB1, T-lymphocyte activation antigen CD80, CD28LG, B7, CD28LG1, LAB7, Activation B7-1 antigen, CTLA-4 counter-receptor B7.1, BU63, B70, CD28LG2, CTLA-4 counter-receptor B7.2, Activation B7-2 antigen, T-lymphocyte activation antigen CD86, CD86, FUN-1
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P33681 & P42081
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BMS-224818,LEA29Y, CAS: 706808-37-9
Clone ID
Belatacept
A randomized, double-blind, placebo-controlled trial of abatacept for the treatment of relapsing, non-severe, granulomatosis with polyangiitis., PMID:40506793
Abatacept and multiple therapeutic bronchoscopies as salvage therapy for refractory tracheobronchial inflammation and stenosis in GPA., PMID:40506105
Optimal GVHD Prophylaxis., PMID:40488825
Allogeneic Transplantation for Older Adults., PMID:40488822
Reduction in Belatacept Dosing Frequency to Every 2 Months for Kidney Transplant Patients at High Risk of Infections., PMID:40483706
Glucocorticoid treatment in early rheumatoid arthritis is independently associated with increased PCSK9 levels: data from a randomised controlled trial., PMID:40480650
Crystalline Nephropathy Due to 2,8-Dihydroxyadeninuria in a Transplanted Kidney: 2 Case Reports., PMID:40478787
Immune Checkpoint Inhibitors for Patients With Preexisting Autoimmune Neurologic Disorders., PMID:40465294
Belatacept in Kidney Transplantation: Reflecting on the Past, Shaping the Future., PMID:40463417
Autoantibodies as prognostic markers in rheumatoid arthritis., PMID:40458132
Switching to IL-6 inhibitors or abatacept in elderly patients with rheumatoid arthritis achieving low disease activity with jak inhibitors: a pilot study., PMID:40455033
Efficacy and Safety of Belatacept in Heart Transplant Recipients., PMID:40446881
Multi-omics analysis of Helicobacter pylori-associated gastric cancer identifies hub genes as a novel therapeutic biomarker., PMID:40445003
FDA Approval Summary: Abatacept for prophylaxis of acute graft versus host disease., PMID:40435096
Interplay of Belatacept Immunosuppression and Maribavir Antiviral Activity in Recurrent CMV Viremia: Clinical Implications and Literature Review., PMID:40431608
New Challenging Systemic Therapies for Juvenile Scleroderma: A Comprehensive Review., PMID:40430462
Inefficiency Rates of Biological Immunosuppressive Induction Agents Used in Organ Transplantation: A Pharmacovigilance Study., PMID:40429403
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 Diabetes., PMID:40424079
Reply to "Real-world registry evidence beware: Old-world risk analysis may not be applicable to new world belatacept utilization"., PMID:40419022
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A report from the CIBMTR., PMID:40398621
Disseminated cat-scratch disease during abatacept therapy for rheumatoid arthritis in an older patient: A case report and review of the literature., PMID:40379021
Humoral immunogenicity after vaccination with the fourth dose of COVID-19 in patients with immunomediated inflammatory diseases., PMID:40378626
A population-based analysis of immunosuppression therapy after organ transplantation., PMID:40375229
Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes., PMID:40374481
Donor-specific mesenchymal stem cell infusion in human and nonhuman primate kidney transplantation., PMID:40368061
Immunosuppressive treatment patterns in kidney transplant recipients in France: an insurance claims database study (OISTER) over a 12 year period., PMID:40358899
Mechanism and clinical utility of abatacept in the treatment of rheumatoid arthritis., PMID:40347194
Belatacept as an alternative immunosuppressive agent for bone marrow-sparing in idiopathic pulmonary fibrosis lung transplant recipients with short telomeres., PMID:40345564
The Role of Abatacept on Inflammation and Fibrosis in Hypochlorous Acid-Induced Fibrosis Mice., PMID:40344312
Abatacept-induced lupus erythematosus tumidus: A case report and literature review., PMID:40342196
Cost evaluation in head and neck cancer clinical trials: implications for high-value care., PMID:40339439
Preclinical mouse models of immune checkpoint inhibitor-associated myocarditis., PMID:40335724
Changes in Chronic Graft-versus-Host Disease Treatment Over Time: A 15-Years Survey Within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland., PMID:40334913
Abatacept for acute graft versus host disease prophylaxis in children with sickle cell disease patients undergoing HLA identical sibling hematopoietic stem cell transplantation., PMID:40301664
SARS-CoV-2 N protein and anti-spike serologies: insights into COVID-19 disease severity and mortality-a secondary analysis of the ACTIV-1 trial., PMID:40297751
Toxoplasma Gondii Replication During Belatacept Treatment in Kidney Transplantation: A Case Report and a Review of the Literature., PMID:40282351
Post-transplant cyclophosphamide, abatacept, and vedolizumab to prevent GVHD after hematopoietic stem cells transplantation in children with acute leukemia: results of a prospective trial., PMID:40281208
Non-TNFi biologic and targeted synthetic DMARDs in rheumatoid arthritis-associated interstitial lung disease: A propensity score-matched, active-comparator, new-user study., PMID:40280051
Short Form-36 psychometric properties in idiopathic inflammatory myopathies: reliability, validity, and responsiveness., PMID:40279268
Real-World Evidence in New Drug and Biologics License Application Approvals During Fiscal Years 2020-2022., PMID:40276902
Abatacept for the treatment of myositis-associated interstitial lung disease (ATtackMy-ILD)., PMID:40272902
Macrophage-Tased Dual-Phase T Cell Immunomodulation to Combat Transplant Rejection., PMID:40264278
Transitional and CD21- PD-1+ B cells are associated with remission in early rheumatoid arthritis., PMID:40259340
Real-world registry evidence beware: Old-world risk analysis may not be applicable to new-world belatacept utilization., PMID:40258574
Recommendations for the use of DMARDs in pregnancy and reproductive health for patients with rheumatic disease: A scoping review., PMID:40256995
Exploring the Impact of Diabetes on Kidney Transplant: Patient Outcomes and Management Strategies., PMID:40255815
Characterising infusion/injection-related reactions in patients with rheumatoid arthritis treated with biologic agents., PMID:40249052
Immune Checkpoint Inhibitor Myocarditis and Left Ventricular Systolic Dysfunction., PMID:40246381
Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation-A Transplant Nephrologist's Perspective., PMID:40243357
For research use only. Not for human or drug use.
